BACKGROUND: Physical examination (PE), mammography (MG), breast magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (PET), and pathologic evaluation are used to assess primary breast cancer. To the authors' knowledge, their accuracy has not been well studied in patients receiving neoadjuvant chemotherapy. Accuracies of each modality in tumor and lymph node assessment in patients with T3/T4 tumors receiving neoadjuvant chemotherapy were compared. METHODS: Forty-five patients of a prospective clinical trial studying T3-T4M0 tumors were included. Patients received neoadjuvant chemotherapy: docetaxel/carboplatin with or without trastuzumab before and/or after surgery (depending on HER-2/neu status and randomization). Tumor measurements by PE, MG, and MRI and lymph node status by PE and PET were obtained before and after neoadjuvant chemotherapy. Concordance among different clinical measurements was assessed and compared with the tumor and lymph node staging by pathology. Spearman correlation (r) and root mean square error (RMSE) were used to measure the accuracy of measurements among all modalities and between modalities and pathologic tumor size. RESULTS: Compared with the tumor size measured by PE, MRI was more accurate than MG at baseline (r=0.559, RMSE=35.4% vs r=0.046, RMSE=66.1%). After neoadjuvant chemotherapy, PE correlated better with pathology than MG or MRI (r=0.655, RMSE=88.6% vs r=0.146, RMSE=147.1% and r=0.364, RMSE=92.6%). Axillary lymph node assessment after neoadjuvant chemotherapy demonstrated high specificity but low sensitivity by PET and PE. CONCLUSIONS: Findings suggested that MRI was a more accurate imaging study at baseline for T3/T4 tumor, and PE correlated best with pathology finding. PET and PE both correctly predicted positive axillary lymph nodes but not negative lymph nodes. Copyright (c) 2009 American Cancer Society.
BACKGROUND: Physical examination (PE), mammography (MG), breast magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (PET), and pathologic evaluation are used to assess primary breast cancer. To the authors' knowledge, their accuracy has not been well studied in patients receiving neoadjuvant chemotherapy. Accuracies of each modality in tumor and lymph node assessment in patients with T3/T4 tumors receiving neoadjuvant chemotherapy were compared. METHODS: Forty-five patients of a prospective clinical trial studying T3-T4M0 tumors were included. Patients received neoadjuvant chemotherapy: docetaxel/carboplatin with or without trastuzumab before and/or after surgery (depending on HER-2/neu status and randomization). Tumor measurements by PE, MG, and MRI and lymph node status by PE and PET were obtained before and after neoadjuvant chemotherapy. Concordance among different clinical measurements was assessed and compared with the tumor and lymph node staging by pathology. Spearman correlation (r) and root mean square error (RMSE) were used to measure the accuracy of measurements among all modalities and between modalities and pathologic tumor size. RESULTS: Compared with the tumor size measured by PE, MRI was more accurate than MG at baseline (r=0.559, RMSE=35.4% vs r=0.046, RMSE=66.1%). After neoadjuvant chemotherapy, PE correlated better with pathology than MG or MRI (r=0.655, RMSE=88.6% vs r=0.146, RMSE=147.1% and r=0.364, RMSE=92.6%). Axillary lymph node assessment after neoadjuvant chemotherapy demonstrated high specificity but low sensitivity by PET and PE. CONCLUSIONS: Findings suggested that MRI was a more accurate imaging study at baseline for T3/T4 tumor, and PE correlated best with pathology finding. PET and PE both correctly predicted positive axillary lymph nodes but not negative lymph nodes. Copyright (c) 2009 American Cancer Society.
Authors: T Nakamura; T Fukutomi; H Tsuda; S Akashi-Tanaka; K Matsuo; C Shimizu; K Miyakawa Journal: Jpn J Clin Oncol Date: 2000-10 Impact factor: 3.019
Authors: Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Dan Sudilovsky; Nola M Hylton Journal: AJR Am J Roentgenol Date: 2002-11 Impact factor: 3.959
Authors: L Esserman; E Kaplan; S Partridge; D Tripathy; H Rugo; J Park; S Hwang; H Kuerer; D Sudilovsky; Y Lu; N Hylton Journal: Ann Surg Oncol Date: 2001-07 Impact factor: 5.344
Authors: C Balu-Maestro; C Chapellier; A Bleuse; I Chanalet; C Chauvel; R Largillier Journal: Breast Cancer Res Treat Date: 2002-03 Impact factor: 4.872
Authors: Mathias K Fehr; Rene Hornung; Zsuzsanna Varga; Daniel Burger; Thomas Hess; Urs Haller; Daniel Fink; Gustav K von Schulthess; Hans C Steinert Journal: Breast J Date: 2004 Mar-Apr Impact factor: 2.431
Authors: Eric L Rosen; Kimberly L Blackwell; Jay A Baker; Mary Scott Soo; Rex C Bentley; Daohai Yu; Thaddeus V Samulski; Mark W Dewhirst Journal: AJR Am J Roentgenol Date: 2003-11 Impact factor: 3.959
Authors: Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Fernanda Relea Calatayud; María Del Mar Muñoz Sánchez; Miguel Ángel Cruz Mora; Germán Andrés Jiménez Londoño; Ruth Espinosa Aunión Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-18 Impact factor: 9.236
Authors: Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-04 Impact factor: 9.236
Authors: Kandace P McGuire; E Shelley Hwang; Alan Cantor; Mehra Golshan; Funda Meric-Bernstam; Janet K Horton; Rita Nanda; Keith D Amos; Andres Forero; Cliff A Hudis; Ingrid Meszoely; Jennifer F De Los Santos Journal: Ann Surg Oncol Date: 2014-07-25 Impact factor: 5.344
Authors: Michael L Marinovich; Petra Macaskill; Les Irwig; Francesco Sardanelli; Eleftherios Mamounas; Gunter von Minckwitz; Valentina Guarneri; Savannah C Partridge; Frances C Wright; Jae Hyuck Choi; Madhumita Bhattacharyya; Laura Martincich; Eren Yeh; Viviana Londero; Nehmat Houssami Journal: BMC Cancer Date: 2015-10-08 Impact factor: 4.430